Donor-specific HLA antibodies: Evaluating the risk for graft loss in renal transplant recipients with isotype switch from complement fixing IgG1/IgG3 to noncomplement fixing IgG2/IgG4 anti-HLA alloantibodies

Transplant International

Volumn 27, Issue 3, 2014, Pages 253-261

  Arnold, Marie Luise ^a   Ntokou, Irma Sofia ^b   Doxiadis, Ilias I N ^c   Spriewald, Bernd M ^a   Boletis, John N ^d   Iniotaki, Aliki G ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b IASO GENERAL HOSPITAL   (Greece)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LAIKO GENERAL HOSPITAL   (Greece)

Author keywords

Anti HLA antibodies; class II antibodies; IgG2 4 alloantibodies; Noncomplement fixing antibodies; renal transplantation

Indexed keywords

ALLOANTIBODY; HLA ANTIGEN; IMMUNOGLOBULIN G;

ADULT; ADVERSE EFFECTS; ANTIBODY SPECIFICITY; BLOOD; CLASSIFICATION; COMPLEMENT ACTIVATION; DONOR; FEMALE; GENE REARRANGEMENT; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HUMAN; IMMUNOLOGY; KAPLAN MEIER METHOD; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

ADULT; ANTIBODY SPECIFICITY; COMPLEMENT ACTIVATION; FEMALE; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; IMMUNOGLOBULIN CLASS SWITCHING; IMMUNOGLOBULIN G; ISOANTIBODIES; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TISSUE DONORS; TRANSPLANTATION IMMUNOLOGY;

EID: 84894086426     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12206     Document Type: Article

References (28)

1. Colvin RB,. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol 2007; 18: 1046.
2. Ozawa M, Terasaki PI, Castro R, et al,. 14th International HLA and Immunogenetics Workshop Prospective Chronic Rejection Project: a three year follow-up analysis. In:, Cecka JM, Terasaki PI, eds. Clinical Transplants. Los Angeles CA: Terasaki Foundation Laboratory, 2007: 255.
3. Zhang X, Valenzuela NM, Reed EF,. HLA class I antibody-mediated endothelial and smooth muscle cell activation. Curr Opin Organ Transplant 2012; 17: 446.
4. Wahrmann M, Bartel G, Exner M, et al,. Clinical relevance of preformed C4d-fixing and non-C4d-fixing HLA single antigen reactivity in renal allograft recipients. Transpl Int 2009; 10: 982.
5. Sutherland SM, Chen G, Sequeira FA, Lou CD, Alexander SR, Tyan DB,. Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr Transplant 2012; 16: 12.
6. Gao Z, McAlister VC, Wright JR, McAlister CC, Peltekian K, MacDonald AS,. Immunoglobulin-G Subclass Antidonor Reactivity in Transplant Recipients. Liver Transpl 2004; 10: 1055.
7. Arnold L, Zacher T, Dechant M, Kalden JR, Doxiadis II, Spriewald BM,. Detection and specification of non complement binding anti-HLA alloantibodies. Hum Immunol 2004; 65: 1288.
8. Griffiths EJ, Nelson RE, Dupont PJ, Warrens AN,. Skewing of pretransplant anti-HLA class I antibodies of immunoglobulin G isotype solely toward immunoglobulin G1 subclass is associated with poorer renal allograft survival. Transplantation 2004; 77: 1771.
9. Smith JD, Hamour IM, Banner NR, Rose ML,. C4d fixing, luminex binding antibodies-a new tool for prediction of graft failure after heart transplantation. Am J Transplant 2007; 7: 2809.
10. Bartel G, Wahrmann M, Schwaiger E, et al,. Solid phase detection of C4d-fixing HLA antibodies to predict rejection in high immunological risk kidney transplant recipients. Transpl Int 2013; 26: 121.
11. Honger G, Wahrmann M, Amico P, Hopfer H, Bohmig GA, Schaub S,. C4d-fixing capability of low-level donor-specific HLA antibodies is not predictive for early antibody-mediated rejection. Transplantation 2010; 89: 1471.
12. Yabu JM, Higgins JP, Chen G, Sequeira F, Busque S, Tyan DB,. C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation 2011; 91: 342.
13. Tangye SG, Ferguson A, Avery DT, Ma CS, Hodgkin PD,. Isotype switching by human B cells is division-associated and regulated by cytokines. J Immunol 2002; 169: 4298.
14. Heinemann FM, Roth I, Rebmann V, et al,. Immunoglobulin isotype-specific characterization of anti-human leukocyte antigen antibodies eluted from explanted renal allografts. Hum Immunol 2007; 68: 500.
15. Arnold ML, Dechant M, Doxiadis II, Spriewald BM,. Prevalence and specificity of immunoglobulin G and immunoglobulin A non-complement-binding anti-HLA alloantibodies in retransplant candidates. Tissue Antigens 2008; 72: 60.
16. Karuppan SS, Ohlman S, Moller E,. The occurrence of cytotoxic and non-complement fixing antibodies in the crossmatch serum of patients with early acute rejection episodes. Transplantation 1992; 54: 839.
17. Lobashevsky A, Rosner K, Goggins W, Higgins N,. Subtypes of immunoglobulin (Ig)-G antibodies against donor class II HLA and cross-match results in three kidney transplant candidates. Transpl Immunol 2010; 23: 81.
18. Ntokou IS, Iniotaki AG, Kontou EN, et al,. Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules. Transpl Int 2011; 24: 1084.
19. Dechant M, Vidarsson G, Stockmeyer B, et al,. Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. Blood 2002; 100: 4574.
20. Kaneku H, O'Leary JG, Taniguchi M, Susskind BM, Terasaki PI, Klintmalm GB,. Donor specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation. Liver Transpl 2012; 18: 984.
21. Stavnezer J, Guikema JE, Schrader CE,. Mechanism and regulation of class switch recombination. Annu Rev Immunol 2008; 26: 261.
22. Coffman RL, Lebman DA, Shrader B,. Transforming growth factor beta specifically enhances IgA production by lipopolysaccharide-stimulated murine B lymphocytes. J Exp Med 1039; 1989: 170.
23. de Menezes-Neves PD, Machado JR, dos Reis MM, Faleriosa AC, de Lima Pereira SA, Rodrigues DB,. Distinct expression of interleukin 17, tumor necrosis factor alpha, transforming growth factor beta and forkhead bos p3 in acute rejection after kidney transplantation. Ann Diagn Pathol 2013; 17: 75.
24. Honger G, Hopfer H, Arnold ML, Spriewald BM, Schaub S, Amico P,. Pretransplant IgG subclasses of donor-specific human leukocyte antigen antibodies and development of antibody-mediated rejection. Transplantation 2011; 92: 41.
25. Otten HG, Verhaar MC, Borst HP, Hene RJ, van Zuilen AD,. Pretransplant donor-specific HLA class-I and -II antibodies are associated with an increased risk for kidney graft failure. Am J Transplant 2012; 12: 1618.
26. Arnold ML, Doxiadis IIN,. Spriewald BM Anti-HLA alloantibodies of the IgA isotype in retransplant candidates 16th IHIW. Int J Immunogenetics 2013; 40: 17.
27. Rahimi S, Qian Z, Layton J, Fox-Talbot K, Baldwin WM 3rd, Wasowska BA,. Noncomplement- and complement-activating antibodies synergize to cause rejection of cardiac allografts. Am J Transplant 2004; 4: 326.
28. Valenzuela , Reed F,. The link between MHC antibodies and cell proliferation. Transplant Rev (Orlando). 2011; 25: 154.